• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Lower; Dow Falls Over 50 Points

    11/27/23 9:46:30 AM ET
    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BDRX alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday.

    Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13% to 14,231.78. The S&P 500 also fell, dropping, 0.25% to 4,548.14.

    Check This Out: IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying

     

    Leading and Lagging Sectors

     

    Communication services shares edged higher on Monday.

    In trading on Monday, energy shares fell by 0.7%.

     

    Top Headline

     

    Shopify Inc (NYSE:SHOP) merchants accomplished a record-breaking $4.1 billion in sales on Black Friday, marking a 22% increase from the previous year.

    Sales peaked when collective sales reached $4.2 million per minute at 12:01 p.m. EST.

     

    Equities Trading UP

     

    RedHill Biopharma Ltd. (NASDAQ:RDHL) shares shot up 130% to $0.7241 after the company announced the FDA has granted five years' market exclusivity for Talicia.

    Shares of Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) got a boost, shooting 75% to $4.69 after the company announced it entered into agreements to acquire an exclusive worldwide license to tolimidone.

    Tharimmune, Inc. (NASDAQ:THAR) shares were also up, gaining 53% to $4.41 after the company reported Phase 1 data on TH104 for chronic pruritis in primary biliary cholangitis.

     

    Equities Trading DOWN

     

    BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares dropped 21% to $0.71 after jumping 144% on Friday.

    Shares of Impel Pharmaceuticals Inc. (NASDAQ:IMPL) were down 14% to $0.73 after gaining 8% on Friday. Impel Pharmaceuticals recently announced exploration of strategic alternatives.

    ProQR Therapeutics N.V. (NASDAQ:PRQR) was down, falling 18% to $1.21.

    Also Check This Out: Top 5 Consumer Stocks That Are Preparing To Pump This Quarter

     

    Commodities

     

    In commodity news, oil traded down 0.3% to $75.34 while gold traded up 0.5% at $2,012.40.

    Silver traded up 2% to $24.82 on Monday while copper fell 0.8% to $3.7595.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.1%, London’s FTSE 100 fell 0.2% while Spain’s IBEX 35 Index rose 0.3% The German DAX fell 0.2% French CAC 40 slipped 0.1%, while Italy’s FTSE MIB Index rose 0.1%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 falling 0.53%, Hong Kong’s Hang Seng Index falling 0.20% and China’s Shanghai Composite Index falling 0.30%. India’s S&P BSE Sensex, meanwhile, fell 0.1%.

    Hong Kong’s trade deficit increased to $25.8 billion in October from $20.9 billion in the year-ago month. Profits earned by Chinese industrial firms fell by 7.8% year-over-year to CNY 6,115.42 billion in the first ten months of 2023, compared to a 9.0 % decline in the previous period.

     

    Economics

     

    Data on new home sales will be released at 10:00 a.m. ET.

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

    Get the next $BDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDRX
    $BGLC
    $IMPL
    $PRQR

    CompanyDatePrice TargetRatingAnalyst
    Shopify Inc.
    $SHOP
    3/12/2026$165.00Overweight
    Piper Sandler
    ProQR Therapeutics N.V.
    $PRQR
    3/12/2026$9.00Outperform
    Oppenheimer
    Shopify Inc.
    $SHOP
    2/17/2026$150.00Hold → Buy
    Truist
    Shopify Inc.
    $SHOP
    2/12/2026$150.00Neutral → Outperform
    Mizuho
    Shopify Inc.
    $SHOP
    2/12/2026$159.00Hold → Buy
    TD Cowen
    Shopify Inc.
    $SHOP
    2/10/2026$150.00Neutral → Buy
    MoffettNathanson
    Shopify Inc.
    $SHOP
    2/2/2026Neutral → Buy
    Arete
    Shopify Inc.
    $SHOP
    1/8/2026Sector Perform → Sector Outperform
    Scotiabank
    More analyst ratings

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    SEC Filings

    View All

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    4/22/26 8:02:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by BioNexus Gene Lab Corp

    10-K - BioNexus Gene Lab Corp (0001737523) (Filer)

    4/14/26 5:20:27 PM ET
    $BGLC
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    4/14/26 7:00:07 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Raday Gilead

    4 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    4/22/26 6:09:14 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Parker Stephen Barry

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/20/26 5:19:51 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Tsimchi Ofer

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/19/26 7:35:14 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Shopify with a new price target

    Piper Sandler resumed coverage of Shopify with a rating of Overweight and set a new price target of $165.00

    3/12/26 8:55:08 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Oppenheimer resumed coverage on ProQR Therapeutics with a new price target

    Oppenheimer resumed coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $9.00

    3/12/26 8:55:08 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shopify upgraded by Truist with a new price target

    Truist upgraded Shopify from Hold to Buy and set a new price target of $150.00

    2/17/26 8:04:32 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

    New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC)The positive NB data from studies undertaken by Penn State University's Jeremy Hengst and Apogee Biotechnology, and funded by the Beat Childhood Cancer Foundation and Four Diamonds, indicate that opaganib may enhance the therapeutic efficacy of the oxaliplatin + doxorubicin (OXDOX) chemotherapy combination in high-risk NB by directly destabilizing n-Myc, a key oncogenic driver of neuroblastoma and other solid tumors, throu

    4/22/26 8:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shopify to Announce First-Quarter 2026 Financial Results May 5, 2026

    Internet, Everywhere, April 14, 2026 (GLOBE NEWSWIRE) -- Shopify Inc. ((NASDAQ, TSX:SHOP) plans to announce financial results for the quarter ended March 31, 2026 before markets open on Tuesday, May 5, 2026. Shopify's management team will host a conference call to discuss first-quarter results at 8:30 a.m. ET on Tuesday, May 5, 2026. The conference call will be available via webcast on the Investor Relations section of Shopify's website at https://www.shopify.com/investors/events. An archived replay of the webcast will be available following the conclusion of the call. About Shopify Shopify provides essential internet infrastructure for commerce. Shopify's all-in-one platform makes it

    4/14/26 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

    AX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indicationAdditional programs advancing toward the clinic, including AX-0811 and AX-0422Axiomer platform supporting multiple additional clinical data readouts within current runway LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its virtual Investor and Analyst event hosted today. During the event, ProQR prov

    4/8/26 4:00:00 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Appajosyula Sireesh bought $90,973 worth of shares (61,496 units at $1.48), increasing direct ownership by 1,824% to 64,868 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:31:11 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

    SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

    11/14/24 12:22:08 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Financials

    Live finance-specific insights

    View All

    Shopify to Announce First-Quarter 2026 Financial Results May 5, 2026

    Internet, Everywhere, April 14, 2026 (GLOBE NEWSWIRE) -- Shopify Inc. ((NASDAQ, TSX:SHOP) plans to announce financial results for the quarter ended March 31, 2026 before markets open on Tuesday, May 5, 2026. Shopify's management team will host a conference call to discuss first-quarter results at 8:30 a.m. ET on Tuesday, May 5, 2026. The conference call will be available via webcast on the Investor Relations section of Shopify's website at https://www.shopify.com/investors/events. An archived replay of the webcast will be available following the conclusion of the call. About Shopify Shopify provides essential internet infrastructure for commerce. Shopify's all-in-one platform makes it

    4/14/26 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Shopify's Standout 2025: The Launchpad for a New Era of Commerce in 2026

    $11.6B in revenue, $2B in free cash flow and the launch of a $2B share repurchase programInternet, Everywhere--(Newsfile Corp. - February 11, 2026) - Shopify Inc. ((NASDAQ, TSX:SHOP) announced today financial results for the quarter and year ended December 31, 2025. Shopify achieved Q4 revenue growth of 31% and a 19% free cash flow margin, marking ten consecutive quarters of double-digit free cash flow margins."2025 was Shopify at full throttle - driving compounding growth, while laying the rails for the new era of AI commerce," said Harley Finkelstein, President of Shopify. "2026 will be the year of the builders, and we'll be powering them - from first sale to full scale."Jeff Hoffmeister,

    2/11/26 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Shopify to Announce Fourth-Quarter and Full-Year 2025 Financial Results February 11, 2026

    Internet, Everywhere--(Newsfile Corp. - January 28, 2026) - Shopify Inc. ((NASDAQ, TSX:SHOP) plans to announce financial results for the quarter and year ended December 31, 2025, before markets open on Wednesday, February 11, 2026. Shopify's management team will host a conference call to discuss fourth-quarter and full-year results at 8:30 a.m. ET on Wednesday, February 11, 2026. The conference call will be available via webcast on the investor relations section of Shopify's website at https://shopifyinvestors.com/news-and-events. An archived replay of the webcast will be available following the conclusion of the call.About ShopifyShopify provides essential internet infrastructure for commer

    1/28/26 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology